Leah Croll, MD, Assistant Professor of Clinical Neurology at the Lewis Katz School of Medicine at Temple University, provided perspective to ABC News about the U.S. Food and Drug Administration (FDA)’s approval of the drug Zavzpret. Zavzpret is the first and only migraine treatment of its kind to be offered in a nasal spray.
Update: Temple Health and Keystone First Family Health Plans have reached a new contract agreement.
Learn More
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH